ClinicalTrials.gg

Lymphoma, B-Cell, Marginal Zone clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 875 studies for Lymphoma, B-Cell, Marginal Zone across more than 10 countries. 111 are recruiting or about to start. 133 of them are mainly about Lymphoma, B-Cell, Marginal Zone (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

ClinicalTrials.gov finds 920 studies for Lymphoma, B-Cell, Marginal Zone. How that becomes 875 here

This page counts the studies the registry files under Lymphoma, B-Cell, Marginal Zone, and those it files under no condition that list Lymphoma, B-Cell, Marginal Zonethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 920Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −4List Lymphoma, B-Cell, Marginal Zone as a condition, but the registry did not file them under itMost often written as “Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive” (1), “Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma” (1), and “Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue” (1). The registry filed them under other conditions only, most often Stomach Neoplasms (1) and Orbital lymphoma (1).
  3. −41Match it another way5 name it in the title, 2 in a keyword, and 34 by a synonym or other text the search reads.
  4. 875The count on this page10 of them list Lymphoma, B-Cell, Marginal Zone in their own words; the registry filed them under no condition.

Status

Completed
496
Terminated
124
Recruiting
92
Active, not recruiting
54
Status unknown
48
Withdrawn
41

Phase

Phase 2
397
Phase 1
364
Phase 3
71
Early Phase 1
6
Phase 4
3

Where

United States
674
Italy
62
France
58
China
58
Germany
45
United Kingdom
43

Who develops what

Add Lymphoma, B-Cell, Marginal Zone to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 10 programs from 10 companies, 1 with this as their studies’ main aim; 1 with a live phase 3 study; 0 primary completions in the next 12 months. Compare AbbVie, Ascentage Pharma Group International and Eli Lilly here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
LenalidomideRecent, repeated
Evidence
  • NCT06149286 · Regeneron Pharmaceuticals · Phase 3 · live · background · “Lenalidomide” · registered Nov 2023
  • NCT06082102 · InnoCare Pharma Limited · Phase 3 · live · comparator · “Lenalidomide” · registered Oct 2023
  • NCT05100862 · BeOne Medicines · Phase 3 · live · comparator · “Lenalidomide” · registered Sep 2021
  • NCT04680052 · Incyte Corporation · Phase 3 · live · background · “lenalidomide” · registered Dec 2020
  • NCT04669171 · Enterome · Phase 2 · live · background · “lenalidomide” · registered Dec 2020
Bristol-Myers Squibb61% of its industry studiesUS: off-patent, 17 generics marketedEU: off-patent, 4 generics authorized22 studies

8 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
mesutoclax☆ Track1 live phase-3 study: NCT07896590InnoCare Pharma Limited

The 1 in phase 3 with the nearest primary completion, of 10 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Lymphoma, B-Cell, Marginal Zone studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 26 open · Antimetabolites 4 open · Alkylating agents 3 open · Antibody-drug conjugates (ADCs) 2 open · Calcineurin inhibitors 36

Coming up

47studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 92 Lymphoma, B-Cell, Marginal Zone studies recruiting now, 77 (84%) set no upper age limit and 7 (8%) stop at 75 or younger. 9 (10%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (3%) take healthy volunteers.

Recruiting studies that take each age, of 92
AgeWomenMen
106 (7%)6 (7%)
1890 (98%)90 (98%)
3091 (99%)91 (99%)
4091 (99%)91 (99%)
5091 (99%)91 (99%)
6591 (99%)91 (99%)
7590 (98%)90 (98%)
8581 (88%)81 (88%)

Across all 875 studies, recruiting or not: 19% stop at 75 or younger and 9% at 65; 22% take children; 0% are for women only and <1% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Lymphoma, B-Cell, Marginal Zone studies take

Of 113 phase 2 interventional studies under Lymphoma, B-Cell, Marginal Zone, half reached primary completion within 69 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 157 mo38–102 · 81 studies—64 mo43–108 · 46 studies
Phase 1/278 mo49–114 · 38 studies——
Phase 269 mo38–110 · 113 studies—73 mo42–117 · 97 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 875. Browse all 875 → or search them.